Pricing

Novavax, Inc (NVAX)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Stanley C. Erck
Employees:
1990
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD, 20878
240-268-2000
Stock Split History
DateRatio
2019-05-10 1:20
Novavax, Inc. focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial. NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate, is in Phase 3 clinical trial. ResVax is a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available